Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and High Dose IFN-alfa2b in Advanced Melanoma
NCT02339324Phase 1Completed
- Start
- Mar 2015
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in melanoma. Primary endpoint: Number of participants who experience adverse events up to 5 years. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02339324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339324.